The FDA Fast-Tracked Three Psychedelic Drugs. That's Not the Same as Approving Them.

In April 2026, the FDA did something it had never done before: it issued national priority vouchers to three companies developing psychedelic-based medicines, under a newly created Commissioner’s National Priority Voucher pilot program. The recipients were Compass Pathways (psilocybin for treatment-resistant depression), the Usona Institute (psilocybin for major depressive disorder), and Transcend Therapeutics (methylone for PTSD). An April 18 executive order directing federal agencies to accelerate the development and approval of psychedelic drugs preceded the vouchers by six days.

The headlines this generated were predictably overheated. A priority voucher is not an approval. It is a mechanism that allows a company to use the voucher to receive expedited FDA review of a future drug application — meaning the FDA commits to reviewing the company’s new drug application within six months rather than the standard ten to twelve. That matters for development timelines. It does not mean the drug has been approved, that it has cleared the clinical hurdles required for approval, or that a patient can receive it in a clinical setting.

What is worth noting: of the three companies, none has yet filed a new drug application. The priority vouchers accelerate the review process once an NDA is filed. Compass Pathways and Usona have both completed Phase 2 trials showing signal for psilocybin in depression; both are in or moving toward Phase 3. Transcend Therapeutics’ methylone program — using a compound closely related to MDMA — is at an earlier stage.

The MDMA precedent is relevant here. Lykos Therapeutics received FDA Breakthrough Therapy designation for MDMA-assisted therapy for PTSD, completed two Phase 3 trials, and was rejected by the FDA in August 2024. The agency’s Complete Response Letter cited issues with trial methodology, assessment of abuse potential, and the representativeness of the study population. A new Phase 3 trial is now required. That process takes years. MDMA is not on a path to approval in the near term.

Psilocybin, based on what’s publicly known about the Phase 2 data, is in better regulatory shape. The neuropsychological mechanism is better understood, the safety profile in clinical settings is cleaner, and the trial designs for the remaining Phase 3 work are more straightforwardly replicable. If Compass Pathways or Usona reaches the NDA stage with clean Phase 3 data and uses its priority voucher, psilocybin could be the first psychedelic drug approved by the FDA for any indication — most likely treatment-resistant depression.

What that means for addiction treatment specifically is a more speculative question. The evidence for psilocybin in AUD and tobacco use disorder is early but encouraging — small studies showing meaningful reductions in drinking and smoking at follow-up points that go out past six months. Those trials are not the Phase 3 trials that will produce the NDA. They’re the science that justifies running them.

The April 2026 developments moved timelines. They didn’t change the fundamental trajectory: psychedelic-assisted therapy is probably three to five years from FDA approval for any indication, and probably longer from insurance coverage or broad clinical availability. The executive order accelerates review; it cannot manufacture Phase 3 data that hasn’t been collected yet.

---

Related: Psychedelics & Empathogens · Science & Medicine